Alkem Laboratories Limited β Q2FY27 earnings call summary
Filed 18 November 2026 Β· Official transcript
- Q2 FY27 revenue INR 4,520 Cr +13.8% y-y; EBITDA INR 1,025 Cr +11.3%, margin 22.5%
- Daman facility remediation ongoing; 8 product launches delayed impacting U.S. growth
- FY27 EBITDA margin guidance maintained at 20-21%; pharma core margin ~26% in Q2
- Occlutech integrated from July 16; gross margin ~80%, U.S. ramp-up expected in 2028
- Non-U.S. markets strong with 58% growth led by LATAM, Australia, Europe; mid-teens growth expected
- Enzene biotech and MedTech drag margins by ~100 bps; break-even expected in 18 months
- U.S. business volume +10%, price erosion 16%, new launches limited by OAI status
- Capex planned: INR 300-350 Cr for Enzene, INR 400 Cr for MedTech over 3-4 years
Open source transcript Β· View Alkem Laboratories Limited research
Sign in free to track Alkem Laboratories Limited and receive future summaries.